Kornimate/medical-research-clean huggingface dataset:
a trial of hrs5580 in prevention of postoperative nausea and vomiting of adults

Conditions: Preventing of Postoperative Nausea and Vomiting in Adults

Summary: the study is being conducted to evaluate the efficacy, and safety of hrs5580 for preventing of postoperative nausea and vomiting in adults. to explore the reasonable dosage of hrs5580 for postoperative nausea and vomiting.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent 2. plan to undergo elective surgery under general anesthesia； 3. ≥18 years old 4. meet the weight standard 5. conform to the asa physical status classification 6. expected postoperative hospital stay ≥72 hours 7. ponv risk factors ≥3 exclusion criteria: 1. subjects with vomiting and/or retching and nausea occurred before surgery 2. subjects with a history of vestibular disease, central nervous system and other system diseases 3. subjects with a previous history of chronic nausea or vomiting/retching 4. subjects with a history of myocardial infarction or unstable angina pectoris 5. subjects with atrioventricular block or cardiac insufficiency 6. subjects with a history of ischemic stroke or transient ischemic attack 7. subjects with poor blood pressure control after medication 8. abnormal electrocardiogram 9. abnormal values in the laboratory 10. allergic to a drug ingredient or component 11. received treatment with potential antiemetic effects before starting the investigational product 12. subjects who received chemotherapy prior to surgery 13. use of drugs that affect the antiemetic effect, and the time between the last use of the test drug and the start of the time is less than 5 half-lives 14. plan to receive local anesthesia only or total intravenous anesthesia only 15. subjects who are expected to require an in-situ nasogastric tube or orogastric tube after completion of surgery 16. subjects expected to be transferred to the icu at the end of surgery 17. pregnant or nursing women 18. no birth control during the specified period of time 19. participated in clinical trials of other drugs (received experimental drugs) 20. the inestigators determined that other conditions were inappropriate for participation in this clinical trial
evaluation of scout ds in subjects with type 2 diabetes #2

Conditions: Diabetes Mellitus, Non-Insulin Dependent

Summary: the primary objective of the trial is to collect scout ds and hemoglobin a1c measurements of subjects who have been diagnosed with type 2 diabetes.

previous studies have excluded subjects with type 2 diabetes. the primary objective of this study is to correct an imbalance in the disease prevalence of the data set used to develop the scout ds diabetes screening algorithm.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years self-reported diagnosis of type 2 diabetes no self-reported diagnosis of type 2 diabetes exclusion criteria: * less than 18 years of age * diagnosed with type 1 diabetes * known to be pregnant (self reported) * receiving dialysis or having known renal compromise * scars, tattoos, rashes or other disruption/discoloration on the left volar forearm. * known to have, or at risk for, photosensitivity reactions ( e.g., sensitive to ultraviolet light, or taking medication known to cause photosensitivity)

Keywords: type 2 diabetes adults 18 years and older taking control of your diabetes health fair
non-selective beta blockers versus evl for primary prophylaxis of esophageal variceal bleeding in patients with hepatocellular carcinoma with portal vein tumour thrombosis.

Conditions: Hepatocellular Carcinoma With Portal Vein Thrombosis

Summary: every patient with hcc (hepato-cellular carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. they will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.


Eligibility criteria:
inclusion criteria: * patients of cirrhosis with hepatocellular carcinoma and portal vein thrombosis * presence of large oesophageal varices or small with high risk exclusion criteria: * any contra-indication to beta-blockers * any endoscopic variceal ligation or sclerotherapy within last 3 months * high risk gastric varices * any past history of transhepatic intrajugular portosystemic shunt or surgery for portal hypertension * significant cardio or pulmonary co-morbidity * any extrahepatic malignancy * patients with past history of variceal bleed * patients with non-tumor portal vein thrombosis * refusal to participate in the study
improving sci rehabilitation interventions by retraining the brain

Conditions: Cervical Spinal Cord Injruy

Summary: the long-term goal of this project is to develop upper limb rehabilitation interventions that can be utilized for cervical spinal cord injury survivors. this study will utilize a novel method of non-invasive brain stimulation in conjunction with upper limb training given for 15 sessions over several weeks up to 8 weeks. the study will include the following site visits: * eligibility screening and informed consent visit. * four testing visit in which motor function of the upper limb and neurophysiology will be measured * fifteen intervention visits during which patients will receive upper limb training in conjunction with non-invasive brain stimulation * repeat testing of motor function and neurophysiology of the upper limb following completion of intervention visits * a follow-up visit completed 3 months after the completion of interventions

this is a phase i/ii multi-site clinical trial. in this phase i/ii randomized controlled study, 49(up to 54) cervical spinal patients with upper limb impairments will receive non-invasive brain stimulation tdcs (transcranial direct current stimulation) to the area in the brain controlling the weaker muscle of the weakest upper limb while receiving training for 15 sessions over several weeks up to 8 weeks. the primary outcome will be motor limb impairment, and secondary outcomes will be tests of functional ability, spinal excitability, and strength and dexterity. safety and feasibility of pairing tdcs with rehabilitation will also be explored and include adverse effects, subject/investigator blinding, and attrition to 3 month follow-up.

Eligibility criteria:
inclusion criteria: * patients with incomplete (having sparing to muscles in the upper extremities below the level of injury) c1-c8 sci * at least 1 year post injury * weakness of the triceps or biceps muscle in the weaker upper limb, defined as a clinically detectable difference in power compared to the power of the spared antagonist(biceps and triceps respectively) muscle, i.e., at least one muscle grade lower on the mrc scale. exclusion criteria: * contraindications to tdcs and tms including: pacemaker, metal in the skull, seizure history, pregnancy. * pressure ulcers * traumatic brain injury (tbi), diagnosed based upon acute injury rancho scale \<5 or positive mri/ct findings at the time of injury will also be excluded to prevent confounding of tms metrics. * excessive tone/spasticity and severe contractures or soft tissue shortening at the elbow/wrist * participating in ongoing upper-limb therapies

Keywords: cervical spinal cord injury tdcs transcranial direct current stimulation upper limb rehabilitation brain stimulation
study of the efficacy of darbepoetin alfa in the treatment of renal anemia

Conditions: Anemia; Kidney Failure, Chronic; Peritoneal Dialysis, Continuous Ambulatory

Summary: anaemia is a common consequence of chronic renal failure. darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropietin and conventional recombinant human erythropoietin (rhuepo). darbepoetin alfa has been shown to have a serum half-life 3-fold longer than that of rhuepo, which allows dosing at extended intervals and less frequent injection. the objective is to evaluate the efficacy and safety of darbepoetin alfa therapy given at an extended once monthly dosing interval in the treatment of renal anaemia in continuous ambulatory peritoneal dialysis.


Eligibility criteria:
inclusion criteria: * patients on continuous ambulatory peritoneal dialysis * patients receiving subcutaneous recombinant human erythropoietin (rhuepo) * patients with haemoglobin level ?10 g/dl and remain stable for the past 3 months while receiving rhuepo exclusion criteria: * uncontrolled hypertension * severe congestive heart failure (nyha class iii or iv) * grand mal epilepsy * any kind of blood loss causing fe depletion * presence of infection, either acute or chronic, or inflammatory conditions within 3 months preceding the study * malignancy * aluminum toxicity * severe hyperparathyroidism with marrow fibrosis or osteitis fibrosa _ pth \> 20 times of normal * vitamin b12 or folate deficiency _ mcv \> 100fl * haemolysis * marrow dysfunction e.g. aplastic anaemia, myelodysplastic syndrome, multiple myeloma, etc * thalassaemia major, intermediate or minor, or red cell enzyme defects * blood transfusion within 3 months preceding the study * pregnancy or lactating mothers

Keywords: anemia end-stage renal failure continuous ambulatory peritoneal dialysis
99mtc-adapt6 spect-based non-invasive quantification of her2-expression in breast cancer with metastatic lymph nodes

Conditions: Breast Cancer; Female

Summary: an open-label, single center study with 99mtc-adapt6 spect and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the her2 expression measured by 99mtc-adapt6 spect and standard histopathology from relevant tumor and lymph node biopsies.

overall goal of the project: to determine her2 expression level in primary breast cancer and axillary lymph node metastases before neoadjuvant targeted (trastuzumab or trastuzumab+pertuzumab) therapy.

Eligibility criteria:
inclusion criteria: 1. subject is \> 18 years of age 2. diagnosis of primary breast cancer with lymph node metastases 3. availability of results from her2 status previously determined on material from the primary tumor and metastatic ln, either a. her2-positive, defined as a dako herceptest™ score of 3+ or fish positive or b. her2-negative, defined as a dako herceptest™ score of 0 or 1+; or else if 2+ then fish negative 4. hematological, liver and renal function test results within the following limits: * white blood cell count: \> 2.0 x 109/l * hemoglobin: \> 80 g/l * platelets: \> 50.0 x 109/l * alt, alp, ast: =\< 5.0 times upper limit of normal * bilirubin =\< 2.0 times upper limit of normal * serum creatinine: within normal limits 5. a negative pregnancy test for all patients of childbearing potential. sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination 7. subject is capable to undergo the diagnostic investigations to be performed in the study 8. informed consent exclusion criteria: 1. any system therapy (chemo-/targeted therapy) 2. second, non-breast malignancy 3. active current autoimmune disease or history of autoimmune disease 4. active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. known hiv positive or chronically active hepatitis b or c 5. administration of other investigational medicinal product within 30 days of screening 6. ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to us national cancer institute's

Keywords: 99mtc-adapt6 breast cancer metastatic lymph nodes her2 expression
50% effective concentration of sevoflurane for immobility

Conditions: Anesthetics, Inhalation

Summary: sevoflurane is as attractive inhalation agent fore deep sedation in children undergoing short invasive procedure because of lack of irritation to the respiratory tract, a pleasant odor and rapid clinical effect and recovery due to low blood gas partition coefficient. the aim of this study is to determine the optimum inspired concentration of sevoflurane required for immobility during botulinum toxin injection in spontaneously breathing children with cerebral palsy.

all anesthetics were administered by a single experienced anesthesiologist. anesthetic induction was performed progressively with inhaled 1-8% sevoflurane, if the patient was cooperative, otherwise directly to the 8%, and subsequent maintenance 2% in oxygen at 5 l /min. a face mask was connected to a mapleson c circuit for it. patients breathed spontaneously, unaided, via a pediatric face mask. a failure was defined as the patient continued to move after following the study protocol for sevoflurane inhalation. insufficient sedation was treated with increments of 0.5% concentration to achieve the desired effect, ie, maintenance of immobility during botulinum toxin injection. the sevoflurane concentration in the next patient would be adjusted depending on the success or failure for immobility at given sevoflurane concentration ( if successful, 0.5% lower concentration, if failed, 0.5% higher concentration). the child was recovered from sevoflurane sedation at the end of botulinum toxin injection and transferred to post-anesthetic care unit.

Eligibility criteria:
inclusion criteria: * 3-12 years old children with cerebral palsy receiving sevoflurane inhalation for botulinum toxin injection * american society of anesthesiologists physical status 1-2 exclusion criteria: * body mass index \> 30 kg/m2 * unstable heart disease * anticipated difficult airway history including congenital facial or airway anomaly * recent upper respiratory tract infection ( \< 2 weeks) * gastroesophageal reflux * allergy history to sevoflurane, remifentanil or any drug used during procedure

Keywords: sevoflurane motion botulinum toxins cerebral palsy
national trends in otitis media in children under 5 years of age

Conditions: Otitis Media; Myringotomy Tube Insertion; Skin Rash; Trauma

Summary: the rationale for this study is to assess the change in ambulatory care visit rates for acute otitis media between the period before (2001-2009) and after the introduction of the 13-valent pneumococcal conjugate vaccine (13vpnc) (2011-2013) among children less than 5 years old in the united states.

namcs-the survey utilizes a three stage sampling design based on (1) probability of selecting a primary sampling unit (psu) (2) probability of selecting a physician within the psu and (3) probability of selecting a patient within the physician practice. this last probability is defined to be the exact number of office visits during physician's specified reporting week divided by the number of patient record forms completed. nhamcs- for producing unbiased national estimate, this survey utilizes four stages (a) probability of selecting a psu (b) probability of selecting a hospital with in psu (c) probability of selecting an emergency department (ed) or outpatient department (opd) within the hospital (d) probability of selecting a visit within ed or opd. the overall probability of selection is the product of the probabilities at each stage. the inverse of the overall selection probability is the basic inflation weight.

Eligibility criteria:
inclusion criteria: five years of age or under at the time of visit, ambulatory visit for otitis media, myringotomy tube insertion, skin rash or trauma during study period exclusion criteria: age over 5 years, no ambulatory visits for the events listed in inclusion criteria

Keywords: ecologic cross sectional trend analysis
parturient satisfaction with epidural analgesia by pcea or manual boluses

Conditions: Labor Pain

Summary: those prospective parturients that express that they may want an epidural labour analgesia for their delivery will be informed about the possibility to choose between a pump driven epidural or midwife administered intermittent boluses.

the purpose is to compare parturient and midwife satisfaction with the epidural labour analgesia when epidural analgesia is maintained by an epidural bolus pump (automated mandatory boluses with patient controlled boluses without background infusion) or midwife administered on-demand boluses.

Eligibility criteria:
inclusion criteria: * age 18 years or older * admitted to the delivery hospital with the prospect of vaginal delivery * on admission when questioned about planned analgesia expresses that may want an epidural analgesia for the planned vaginal delivery * after reading the study prochure signs the participation (consent) form * sufficient command of finnish or swedish to facilitate interview exclusion criteria: * contraindications for epidural analgesia * planned cesarean delivery * age under 18 years

Keywords: epidural analgesia labour epidural patient controlled epidural
effect of dietary fat when eaten with fructose versus glucose

Conditions: Body Weight Changes

Summary: this study is designed to test the effects on liver fat of varying fat intake in the presence of fructose or glucose. we hypothesize that higher dietary fat when eaten with fructose as compared to glucose will increase the amount of hepatic lipid as measured by magnetic resonance spectroscopy.

after 2 screening visits including an exercise test, dexa and ct scan, qualifiers begin a 7 day diet with 20% fat, 65% carbohydrate (with 20% glucose) and 15 % protein. participants consume 2 meals per day at pbrc with lunch and weekend meals packed to go. following a test day, participants are randomized to one of 3 diet assignments and then test again: 1)20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein 2)40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein 3)40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein on day 7 and again 14 days later participants have labs, an oral glucose tolerance test, hepatic and intramuscular lipid measures by mrs, vital signs and waist measurement.

Eligibility criteria:
inclusion criteria: * bmi between 25 and 35 kg/m2 inclusive * at least one of the following: 1. impaired fasting glucose between 100-125 mg/dl inclusive 2. hdl below 40 mg/dl for men or below 50 mg/dl for females 3. triglycerides between 150 mg/dl and 400 mg/dl inclusive 4. blood pressure above or equal to 135 / 85 mm hg * waist circumference \>94cm (37 inches) for men or \>80cm for women * mainly healthy exclusion criteria: * unable or unlikely to eat study foods and only foods provided by prbc * taking routine medications except birth control pills * smoke, abuse drugs,or alcohol * pregnant or breastfeeding, irregular menstrual cycles, post-menopausal,or pcos * diabetes, heart, lung, liver, blood, or kidney disease

Keywords: fructose glucose
metabolic, vascular and cognitive effects of treatment with anthocyanins

Conditions: Coronary Disease; Inflammation; Cognitive Impairment

Summary: the purpose of this study is to examine weather treatment with anthocyanins will affect lipid profile, markers of inflammation and oxidative stress in addition to antioxidative level in serum to the better in persons with increased risk of dementia. the purpose of this study is to examine weather treatment with anthocyanins will increase the score of relevant tests of cognitive function. the investigators will do an open pilot study where patients receive anthocyanin for 16 weeks. 34 patients are expected to be included. in addition we will include 20 healthy controls.

design, method and material: the investigators will first do an open pilot study where 30 people will receive anthocyanins for 16 weeks. the investigators aim to recruit persons with increased risk of cognitive reduction: persons over 50 years with stable coronary heart disease (cad) from the cardiology department stavanger university hospital. in addition will persons with mild cognitive impairment or mild dementia be included from the memory outpatient clinic, stavanger university hospital. blood will be taken by venepuncture by an experienced nurse, centrifuged and handled in according to standardized procedures. the patients will be tested in relevant tests of cognitive function at inclusion and after 16 weeks. at inclusion the patients will be tested in mini mental state examination (mmse) and geriatric depression scale (gds) to make sure that the patients meet the inclusion criteria. at inclusion and after 16 weeks the patients will be tested in word list memory word list recall word list recognition, trail making test a + b and stroop word and colour test. from the healthy controls blood will be taken at inclusion and study end.

Eligibility criteria:
inclusion criteria: * age above 50 years and coronary suspect chest pain with angiographically cad without physiologically stenosis * mild cognitive impairment (icd 10) or mild dementia, defined as fulfilling the dementia criteria (icd 10) but with an mmse score of 24 or higher. * stable medical treatment for the last 3 months. exclusion criteria: * moderate to severe dementia (mmse \< 24) * clinical significant depression (gds-15 score of 7 or higher) * unstable coronary heart disease * heart failure in need of treatment * inflammatory illnesses such at rheumatoid arthritis etc. * another severe illness with \< 5 year expected survival time.
cp4071 in treating patients with locally advanced or metastatic soft tissue sarcoma

Conditions: Sarcoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase ii trial to study the effectiveness of cp4071 in treating patients who have locally advanced or metastatic soft tissue sarcoma.

objectives: * determine the efficacy, in terms of response rate, of cp4071 in patients with previously treated, locally advanced or metastatic soft tissue sarcoma. * determine the clinical toxic effects of this drug in these patients. outline: patients receive oral cp4071 daily. treatment continues in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 25 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed soft tissue sarcoma * metastatic or locally advanced * failed at least 1 prior therapy * measurable disease outside prior irradiation field * no cns metastases patient characteristics: age: * 18 and over performance status: * swog 0-2 life expectancy: * not specified hematopoietic: * not specified hepatic: * bilirubin no greater than 2 times upper limit of normal (uln) renal: * creatinine less than 1.5 times uln * calcium less than uln * potassium normal other: * no other malignancy within the past 5 years except stage i or ii cancer in complete remission, carcinoma in situ of the cervix, or basal cell or squamous cell skin cancer * not pregnant or nursing * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * prior biologic response modifier therapy allowed chemotherapy: * no more than 3 prior chemotherapy regimens for advanced, recurrent, or metastatic disease * no other concurrent chemotherapy endocrine therapy: * no concurrent hormonal therapy for malignancy radiotherapy: * see disease characteristics * at least 3 weeks since prior radiotherapy and recovered * no concurrent radiotherapy surgery: * at least 4 weeks since prior surgery and recovered other: * no other concurrent cardiac glycosides

Keywords: stage iii adult soft tissue sarcoma recurrent adult soft tissue sarcoma stage iv adult soft tissue sarcoma